BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

NCT ID: NCT02341534

Last Updated: 2023-04-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

802 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-07

Study Completion Date

2021-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The BIO\|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors, decreases the risk of major adverse cardiac events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients randomized to the BioMonitor arm will receive an implantable cardiac monitor (ICM; BioMonitor) with remote monitoring function (Home Monitoring®). If the device detects and reports an arrhythmia, patients will be appropriately examined and treated. Patients randomized to the control arm will receive best proven treatment, but no implantable cardiac monitor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Myocardial Infarction, Acute Myocardial Infarction Old

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors
An independent Endpoint Committee was installed to evaluate all reported cardiovascular and serious AEs. The information provided to the Committee did not contain information about the group assigment of the patients.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BioMonitor arm

BioMonitor group (implantation with investigational device + transfer of information via Home Monitoring)

Group Type OTHER

BioMonitor

Intervention Type DEVICE

Patients will be implanted with the BioMonitor + Home Monitoring feature

Control arm

Control group (standard of care)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioMonitor

Patients will be implanted with the BioMonitor + Home Monitoring feature

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has a history of MI according to guidelines
* CHA2DS2-VASc-Score ≥ 4 in men / ≥ 5 in women
* LVEF \> 35 % as estimated within 6 months before enrollment but after conclusion of AMI treatment
* Patient accepts activation of Home Monitoring®
* Patient is able to understand the nature of the clinical study and has provided written informed consent

Exclusion Criteria

* Patients with hemorrhagic diathesis
* Permanent oral anticoagulation treatment for atrial fibrillation
* Indication for chronic renal dialysis
* Pacemaker or ICD implanted or indication for implantation
* Parkinson's disease
* Life expectancy \< 1 year
* Participation in another interventional clinical Investigation
* Age \< 18 years
* Woman who are pregnant or breast feeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IHF GmbH - Institut für Herzinfarktforschung

OTHER

Sponsor Role collaborator

Qmed Consulting A/S

INDUSTRY

Sponsor Role collaborator

Biotronik SE & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian Jons, Doctor

Role: STUDY_CHAIR

Rigshospitalet; Denmark; Copenhagen

Steffen Behrens, Professor

Role: PRINCIPAL_INVESTIGATOR

Vivantes Humboldt Klinikum, Germany, Berlin

Poul Erik Bloch Thomsen, Professor

Role: STUDY_DIRECTOR

Aalborg University Hospital, Denmark, Aalborg

Peter Sogaard, Professor

Role: PRINCIPAL_INVESTIGATOR

Aalborg University Hospital, Denmark, Aalborg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gateway Cardiology

St Louis, Missouri, United States

Site Status

St. Louis Heart and Vascular

St Louis, Missouri, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Altru Health System

Grand Forks, North Dakota, United States

Site Status

Abington Medical Specialists

Abington, Pennsylvania, United States

Site Status

Carolina Heart Specialists

Lancaster, South Carolina, United States

Site Status

Carolina Cardiology Associates

Rock Hill, South Carolina, United States

Site Status

Metro Knoxville HMA LLC

Knoxville, Tennessee, United States

Site Status

Lyell McEwin Hospital (LMH)

Elizabeth Vale, South Australia, Australia

Site Status

East Metropolitan Health Service Trading AS Royal Perth HOSPITAL

Perth, Western Australia, Australia

Site Status

The Canberra Hospital

Canberra, , Australia

Site Status

Kepler Universitätsklinikum

Linz, Upper Austria, Austria

Site Status

OLV Ziekenhuis Aalst

Aalst, , Belgium

Site Status

Ziekenhuis Oost Limburg Genk (ZOL Genk)

Genk, , Belgium

Site Status

Nemocnice České Budějovice

České Budějovice, , Czechia

Site Status

Fakultní nemocnice Olomouc

Olomouc, , Czechia

Site Status

Institute for Clinical and Experimental Medicine (IKEM)

Prague, , Czechia

Site Status

Odense University Hospital (OUH)

Odense, Region Syddanmark, Denmark

Site Status

Aalborg Universitetshospitel

Aalborg, , Denmark

Site Status

Århus Universitetshospital

Århus N, , Denmark

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

Regionshospitalet Herning

Herning, , Denmark

Site Status

Sjaellands Universitets Hospital, Roskilde

Roskilde, , Denmark

Site Status

Regionshospitalet Viborg

Viborg, , Denmark

Site Status

CHRU de Tours - Hôpital Trousseau

Chambray-lès-Tours, , France

Site Status

Hôpital Gabriel Montpied, Clermont Ferrand

Clermont-Ferrand, , France

Site Status

Zentralklinik Bad Berka GmbH

Bad Berka, , Germany

Site Status

Herz- und Gefäß- Klinik GmbH Bad Neustadt

Bad Neustadt A.d. Saale, , Germany

Site Status

Charité Universitätsklinikum - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Vivantes Humboldt-Klinikum

Berlin, , Germany

Site Status

Vivantes-Krankenhaus Spandau

Berlin, , Germany

Site Status

Städtisches Krankenhaus Bielefeld-Mitte

Bielefeld, , Germany

Site Status

Klinikum Coburg

Coburg, , Germany

Site Status

Klinikum Fürth

Fürth, , Germany

Site Status

SRH Wald-Klinikum Gera GmbH

Gera, , Germany

Site Status

Ernst-Moritz-Arndt-Universität Greifswald

Greifswald, , Germany

Site Status

Klinikum der Universität Jena

Jena, , Germany

Site Status

Herzzentrum Leipzig GmbH

Leipzig, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein (UKSH) - Campus Lübeck

Lübeck, , Germany

Site Status

Johannes Wesling Klinikum Minden

Minden, , Germany

Site Status

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

Villingen-Schwenningen, , Germany

Site Status

Universitätsklinikum Würzburg

Würzburg, , Germany

Site Status

National Hospital of Cardiology

Balatonfüred, , Hungary

Site Status

Gottsegen György

Budapest, , Hungary

Site Status

Semmelweis Medical University

Budapest, , Hungary

Site Status

Hungarian Defence Forces Military Hospital

Budapest, , Hungary

Site Status

The Debrecen University of Medicine

Debrecen, , Hungary

Site Status

The University of Pécs

Pécs, , Hungary

Site Status

Pauls Stradins Clinical University Hospital

Riga, , Latvia

Site Status

Riga East Clinical University Hospital

Riga, , Latvia

Site Status

Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG)

Amsterdam, , Netherlands

Site Status

Scheperziekenhuis, Treant Zorggroep

Emmen, , Netherlands

Site Status

Klinika i Katedra Chorób Wewn. i Kardiologii

Warsaw, , Poland

Site Status

National Institute of Cardiology

Warsaw, , Poland

Site Status

SÚSCCH

Banská Bystrica, , Slovakia

Site Status

East-Slovak Cardiology Institute (VUSCH)

Košice, , Slovakia

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital de la Princesa

Madrid, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Czechia Denmark France Germany Hungary Latvia Netherlands Poland Slovakia Spain

References

Explore related publications, articles, or registry entries linked to this study.

Jons C, Bloch Thomsen PE, Riahi S, Smilde T, Bach U, Jacobsen PK, Taborsky M, Falukozy J, Wiemer M, Christensen PD, Konyi A, Schelfaut D, Bulava A, Grabowski M, Merkely B, Nuyens D, Mahajan R, Nagel P, Tilz R, Malczynski J, Steinwender C, Brachmann J, Serota H, Schrader J, Behrens S, Sogaard P. Arrhythmia monitoring and outcome after myocardial infarction (BIO|GUARD-MI): a randomized trial. Front Cardiovasc Med. 2024 May 13;11:1300074. doi: 10.3389/fcvm.2024.1300074. eCollection 2024.

Reference Type DERIVED
PMID: 38807948 (View on PubMed)

Jons C, Sogaard P, Behrens S, Schrader J, Mrosk S, Bloch Thomsen PE. The clinical effect of arrhythmia monitoring after myocardial infarction (BIO-GUARD|MI):study protocol for a randomized controlled trial. Trials. 2019 Sep 11;20(1):563. doi: 10.1186/s13063-019-3644-5.

Reference Type DERIVED
PMID: 31511057 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol: Study Protocol used in the USA

View Document

Document Type: Study Protocol: Modification to study protocol used in the USA

View Document

Document Type: Study Protocol: Study Protocol used outside the USA (OUS)

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Preserved Ejection Fraction

Identifier Type: OTHER

Identifier Source: secondary_id

Implantable Cardiac Device

Identifier Type: OTHER

Identifier Source: secondary_id

Loop Recorder

Identifier Type: OTHER

Identifier Source: secondary_id

ICM

Identifier Type: OTHER

Identifier Source: secondary_id

HS058

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BioMonitor Master Study
NCT01725568 COMPLETED
BIO.MASTER.BioMonitor 2 Study
NCT02565238 COMPLETED